UroGen Pharma Ltd. (URGN) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. UroGen Pharma Ltd. is a biotechnology company focused on developing and commercializing innovative solutions for urothelial and specialty cancers. The company's primary commercial product is Jelmyto (mitomycin) for pyelocalyceal solution, approved for low-grade upper tract urothelial cancer (UTUC). Its lead product candidate, UGN-102, is in Phase 3 development for low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC).
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $21.8 million | $21.1 million | $40.6 million | $38.3 million |
| Gross Profit | $19.6 million | $18.7 million | $36.7 million | $33.6 million |
| Operating Loss | $(25.8) million | $(15.4) million | $(51.6) million | $(37.4) million |
| Net Loss | $(33.4) million | $(24.1) million | $(65.7) million | $(54.3) million |
| Diluted EPS | $(0.91) | $(1.03) | $(1.87) | $(2.33) |
| Cash & Equivalents | $220.0 million (as of June 30, 2024) | |||
| Marketable Securities | ||||
| Total Liquidity | $241.3 million (Cash + Marketable Securities) | |||
| Long-Term Debt | $97.8 million (Pharmakon loan) | |||
| Prepaid Forward Obligation | $115.9 million (RTW obligation) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 3.3% year-over-year for the quarter and 6.0% year-over-year for the six months, driven by increased sales volume of Jelmyto.
- Expense Increases: Operating expenses rose significantly. Research and Development (R&D) expenses increased by $3.8 million (Q2) and $6.8 million (YTD) due to manufacturing costs for UGN-102 and initiation of Phase 3 studies for UGN-103. Selling, General, and Administrative (SG&A) expenses increased by $4.9 million (Q2) and $7.9 million (YTD) due to UGN-102 brand marketing and commercial operations.
- Financing Activity: The company raised substantial capital in Q2 2024. It completed an underwritten public offering of 5 million shares and pre-funded warrants, raising gross proceeds of $107.5 million. Additionally, the underwriters exercised their option to purchase an additional 921,428 shares in July 2024 for $16.1 million. The company also sold shares under its ATM agreement in Q1 2024.
- Debt Restructuring: In March 2024, the company amended its loan agreement with Pharmakon, adding two new tranches ($25 million required by Sept 2024; $75 million contingent on UGN-102 approval). This amendment reduced the interest rate margin, contributing to a decrease in interest expense.
Guidance, Outlook, and Risks
- UGN-102 NDA Submission: The company expects to complete the submission of a rolling New Drug Application (NDA) for UGN-102 in Q3 2024. Potential FDA acceptance is expected in Q4 2024, with potential approval in Q1 2025 (priority review) or Q2 2025 (standard review).
- UGN-103/104 Pipeline: The company entered a licensing agreement with medac for next-generation formulations. A Phase 3 study for UGN-103 is expected to begin dosing in Q3 2024.
- Legal Proceedings: UroGen filed a lawsuit in April 2024 against Teva Pharmaceuticals regarding a Paragraph IV certification for a generic version of Jelmyto. Teva alleges invalidity of two patents expiring in 2031. UroGen seeks to prevent generic market entry prior to patent expiry.
- Liquidity Outlook: Management believes current cash and marketable securities ($241.3 million) are sufficient to fund operations for more than 12 months. However, the company may need to raise additional capital in the future.
- Risk Factors: Key risks include the uncertainty of UGN-102 regulatory approval, potential generic competition for Jelmyto post-2027, reliance on single-source suppliers for key components, and geopolitical instability in Israel where R&D and some suppliers are located.
Investor Verification Checklist
- Verify the timeline and status of the rolling NDA submission for UGN-102 and any FDA feedback received.
- Monitor the progress of the patent infringement lawsuit against Teva Pharmaceuticals regarding Jelmyto.
- Review the terms of the amended Pharmakon loan agreement, specifically the conditions for the $75 million fourth tranche (contingent on UGN-102 approval by June 30, 2025).
- Assess the impact of the RTW Prepaid Forward Obligation ($115.9 million liability) on future cash flows as Jelmyto sales grow.
- Confirm the company's ability to secure second-source suppliers for critical components like the hydrogel and mitomycin API to mitigate supply chain risks.